The Food and Drug Administration is now investigating an array of fraudulent schemes that appear to be trafficking counterfeit versions of Ozempic, an industry trade group recently warned its members.

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

*Note- this is an early release from the Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting in Hamburg, October 2-6. Please credit the meeting if you use this story* A ...

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity. Rising ...

The US Food and Drug Administration has approved a higher 2-mg dose of the GLP-1 agonist semaglutide (Ozempic, Novo Nordisk) for adults with type 2 diabetes, giving a higher-dose alternative to the ...

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy ®) achieved significant weight loss, with one in three study participants losing 20% or more body weight 1 ** Oral semaglutide 25 mg ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — A weekly glucagon/GLP-1 dual receptor ...

Novo Nordisk officials believe the new therapy will fufill an unmet need for patients with type 2 diabetes and obesity who need a GLP-1 receptor agonist but do not wish to use an injectable drug. FDA ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-weekly 2 mg semaglutide injection in conjunction with diet and exercise to lower ...

Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for ...